Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 2 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

Recs

2
Player Avatar zzlangerhans (99.67) Submitted: 9/12/2011 3:47:52 PM : Outperform Start Price: $1.32 SNSS Score: +141.52

It's been a steep decline for Sunesis as investors balk at the long wait before the VALOR phase III trial of vosaroxin in AML in 2013. I'm not ready to buy here either, as I've seen the market caps of similar companies drop well below cash. But I'm now using CAPS as a quick reference diary of my biotech analyses, having given up on the value of scores and ratings. This green thumb will keep Sunesis on my watchlist for a potential buy at some point in 2012 if the enterprise value remains minimal.

Featured Broker Partners


Advertisement